Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma entered into an option and license agreement with Sentynl Therapeutics for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD. Sentynl will fund the Phase 3 development program, and Mereo is eligible to receive up to $40 million in upfront and R&D payments upon option exercise, in addition to double-digit royalties on U.S. sales.
Key figures
- Drug Name
- alvelestat
- Deal Value Usd
- $40 million
- Phase Of Trial
- Phase 3
- Prevalence us
- 50,000-80,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.